CompletedPhase 1ACTRN12605000793617

Phase I dose-escalation study for CYT997

Phase I dose-escalation study of CYT997 given as a 24-hour intravenous infusion every three weeks in patients with advanced solid tumours

Sponsor

Cytopia Research Pty Ltd

Enrollment

24 participants

Start Date

Jun 14, 2005

Study Type

Interventional

Conditions

Cancer - solid malignancies that are metastatic or unresectable

Summary

CYT997 is an experimental anticancer agent with vascular targetting activity. This Phase I trial aims to determine the safety and tolerability of CYT997 when given as a 24-hour intravenous infusion.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Phase I dose-escalation study for CYT997. You may be eligible if you are adults aged 18 and older. Participation typically involves medical assessments, possible treatment with the study intervention, and follow-up visits to track your health.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

CYT997 administered as a 24 hour intravenous infusion every three weeks

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000793617